GSK and Empirico Collaborate on Oligonucleotide Candidate
GSK plc and Empirico Inc. have entered into a worldwide exclusive license agreement for EMP-012, a highly selective siRNA oligonucleotide.
EMP-012 addresses a novel therapeutic target and is currently in a phase I trial for the treatment of chronic obstructive pulmonary disease (COPD), with potential expansion into other inflammatory respiratory diseases.
Medical need in COPD remains high despite ongoing innovation.
GSK and Empirico aim to treat respiratory diseases with this collaboration.
Author's summary: GSK and Empirico partner on siRNA oligonucleotide.
More News
- Uzbekistan, UNESCO strengthen partnership in education and culture
- Will ARC Raiders Survive? A Deep Dive Into Its Future | Invision Game Community
- Aspiring Teacher, Student Leader, Lacrosse Standout, Tess Brown ’26 Selected to Attend NCAA Program
- STORM WATCH: Strong wind gusts up to 50 mph, heavy rain passes across NJ today
- Election Guide 2025: Nassau County Legislature District 7 candidate Alec Fischthal, Dem.
- Uzbekistan, Slovakia seek to break new ground in trade and digital collaboration
- Asim Qureshi · Short Cuts: Misuses of the Terrorism Act
- Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times - Clinical Insights for Eye Specialists
- New SMA and RP-SMA FT connectors provide fast and easy assembly
- Why does Spanish pop-star Rosalía sing in German in her latest single?